Zendron 150 mg (Ibandronate Sodium Hydrate)
Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Celix Co., Ltd.
MFDS item code 201404011 · Approved 2014.08.28
This product's status changed to Expired on 2024.08.28. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of osteoporosis in postmenopausal women
Osteoporosis in postmenopausal women is a condition that can easily lead to fractures due to decreased bone density. This medication helps to increase bone density and strengthen bones, thereby reducing the risk of fractures. It also inhibits the progression of osteoporosis, allowing for the maintenance of healthy bones. Regular usage is effective in preventing fractures and contributes to improving the quality of life for patients. This medication is used for the treatment of osteoporosis in postmenopausal women.
Take 1 tablet once monthly, regularly on the same day each month in the morning, with plenty of water at least 1 hour before consuming food, beverages (other than water), or other oral medicines or dietary supplements (including calcium): - This medicine must be swallowed with a sufficient amount of water (180-240ml) while standing or sitting upright, and you must not lie down for 60 minutes after taking it. - Take this medicine with plain water, as mineral water may reduce its absorption. - Do not chew or suck the tablet, to avoid esophageal ulcers. If the patient forgets to take a dose on the regularly scheduled day: - If 8 days or more remain until the next regularly scheduled dose, take 1 tablet the morning after realizing that the dose was missed, and thereafter take 1 tablet each month on the originally scheduled regular dosing day. - If 7 days or fewer remain until the next regularly scheduled dose, take 1 tablet on the next regularly scheduled dosing day, and thereafter take 1 tablet each month on the originally scheduled regular dosing day. - Do not take 2 tablets in the same week. Patients with inadequate dietary intake should supplement calcium or vitamin D, etc. Patients with hepatic impairment No dose adjustment is required. Patients with renal impairment No dose adjustment is required in patients with mild or moderate renal impairment with creatinine clearance of 30mL/min or higher. Use of this medicine is not recommended in patients with creatinine clearance below 30mL/min, as clinical experience is insufficient. Elderly patients No dose adjustment is required.
Children 18 years of age or younger: Efficacy and safety have not been studied.
This medication should not be administered to certain patients. For example, individuals who are allergic to this medication or its components, those with low calcium levels, and those who cannot sit or stand upright for more than 60 minutes should avoid taking this medication. Additionally, patients with esophageal function issues that affect the ability to swallow food should not use this medication. It contains lactose and should be avoided by patients with lactose intolerance or related genetic disorders. Use this medication cautiously in patients with significantly impaired kidney function, and ensure calcium levels are normalized and any bone and mineral metabolism disorders are treated before initiating treatment. This medication may irritate the gastrointestinal tract; therefore, patients with upper gastrointestinal diseases such as gastritis, esophagitis, or esophageal ulcers should take it with caution. If difficulty swallowing, pain, chest pain, or heartburn occurs during use, discontinue and consult a physician immediately. Taking this medication with calcium, milk, antacids, etc., may reduce absorption, so it's important not to consume other foods or drugs for at least 1 hour after taking it. While taking this medication, side effects such as muscle pain, joint pain, headache, indigestion, nausea, diarrhea may occur, and in rare cases, osteonecrosis of the jaw or surrounding bones may occur, so consult a physician before any dental treatments. Women who are pregnant or breastfeeding are advised not to use this medication, and the safety for children and adolescents under 18 has not been established. In the event of an overdose, gastrointestinal discomfort and hypocalcemia may occur, so caution is advised, and the effects on driving or operating machinery are unknown. Store this medication out of reach of children, and properly dispose of any unused medications to prevent environmental contamination.
dyspepsia, nausea, abdominal pain, diarrhea, bloating, gastroesophageal reflux disease, headache, influenza-like illness, fatigue, myalgia, arthralgia, rash, gastritis, esophagitis, muscle cramps, musculoskeletal pain, musculoskeletal rigidity, dysphagia, vomiting, esophageal ulcer, stricture, dizziness, low back pain, duodenitis, hypersensitivity reaction, angioedema, facial swelling, urticaria, uveitis, scleritis, osteonecrosis of the jaw and external auditory canal, anaphylactic reaction, shock, allergic reaction, Stevens-Johnson syndrome, erythema multiforme, vesicular dermatitis, atypical femoral shaft and neck fractures, visual disturbances, myasthenia, pruritus
Not everyone experiences these, and they can vary from person to person.
This medication must be stored in a tightly sealed container to protect it from air and moisture. It's best to maintain a storage temperature between 1 to 30 degrees Celsius. Proper storage ensures the longevity of the medication's effectiveness.
White elongated film-coated tablet
1 tablet/PTP
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Celix Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Jeil Pharmaceutical Co., Ltd.
Ibandronate Sodium Monohydrate 3.375mg
Solution · Prescription medication
Jeil Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Chodang Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Shinpoong Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Ajou Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Aliko Pharmaceutical Co., Ltd.

Ibandronate Sodium Monohydrate 168.75mg
Tablet · Prescription medication
Teragen Etex Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.